Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (" Red Light Holland " or the " Company "), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its audited annual consolidated financial statements and management's discussion and analysis (" MD&A ") for the fiscal years ended March 31, 2026 and 2025. All figures are reported in Canadian dollars. The Company's audited consolidated financial statements and MD&A are available on the Company's website at www.RedLight.co and under the Company's profile on SEDAR+ at www.sedarplus.ca . Following its acquisition of Filament Health Corp. (" Filament "), the Company has expanded its pharmaceutical grade manufacturing, regulatory and clinical research capabilities, including capabilities related to naturally derived psilocybin development and Filament's botanical drug candidate, PEX010, in compliance with applicable laws. The Company's previously approved corporate rebrand to Rhelion Life Sciences Corp. is expected to take effect on August 4, 2026, reflecting the Company's evolution into a science-first life sciences organization dedicated to advancing naturally derived psychedelic medicines. The Company's shares will continue trading under TRIP on the Canadian Securities Exchange, TRUFF on the OTCQB and 4YX on the Frankfurt Stock Exchange. For more information, please visit www.RedLight.co and www.Rhelion.com . Fiscal 2026 marked the successful execution of a strategic vision that has been years in the making. During the year, the Company continued simplifying its legacy operating businesses while establishing a vertically integrated platform focused on naturally derived psychedelic drug discovery, pharmaceutical manufacturing, intellectual property and clinical development. The Filament Acquisition Creates the Foundation for Rhelion The acquisition of Filament Health fundamentally transforms the Company. With Filament now integrated into the business, the Company has a pharmaceutical platform that combines proprietary intellectual property, GMP manufacturing capabilities, regulatory expertise, naturally derived drug candidates and an expanding international research network. Key highlights of the combined platform include: 76 issued patents across 13 patent families Proprietary naturally derived botanical drug candidate PEX010 Successfully completed Phase I clinical development Phase II-ready development programs A Health Canada Level 8 Controlled Substances Dealer's Licence, strengthening the Company's regulatory and production capabilities with Filament's Vancouver-based laboratory and manufacturing facility GMP pharmaceutical grade manufacturing infrastructure Botanical psilocybin capsule manufacturing ranging from 0.5 mg to 25 mg Pharmaceutical grade supply supporting more than 80 clinical studies worldwide FDA regulatory experience and international clinical development expertise A growing network of pharmaceutical supply agreements, licensing opportunities, compassionate use and academic collaborations across North America, Europe and Oceania Management believes these capabilities position the Company to participate in the continued development of the regulated psychedelic medicine sector through an integrated platform combining naturally derived psychedelic drug discovery, pharmaceutical grade manufacturing, intellectual property development, clinical research and regulated distribution. Building Scientific Momentum: Throughout fiscal 2026, the Company continued expanding its scientific and commercial reach through new research collaborations, pharmaceutical grade supply agreements and international partnerships. These initiatives include continued support for more than 80 clinical studies utilizing Filament's botanical drug candidates, expanded international collaborations, and preparations for additional Phase II clinical development i...